TEVA-BUSPIRONE 10 MG
BUSPIRONE HYDROCHLORIDE : 10 MG · DIN 02231492 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is TEVA-BUSPIRONE?
TEVA-BUSPIRONE 10 MG contains BUSPIRONE HYDROCHLORIDE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02231492, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 04-Jun-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-BUSPIRONE used for?
Short term symptomatic relief of excessive anxiety in patients with Generalized Anxiety Disorder. Effectiveness beyond 4 weeks not evaluated.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is TEVA-BUSPIRONE called?
The same molecule, BUSPIRONE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Buspar | Latin | South Africa |
| Pasrin | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02231492 |
|---|---|
| Brand name | TEVA-BUSPIRONE |
| Generic / active ingredient | BUSPIRONE HYDROCHLORIDE : 10 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 10 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N05BE01 BUSPIRONE |
| AHFS class | 28:24.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 04-Jun-2015 |
| Original market date | 1997-09-02 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02231492 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2231492 |
| Brand name | TEVA-BUSPIRONE |
| Active ingredient / INN | BUSPIRONE HYDROCHLORIDE : 10 MG |
| ATC code | N05BE01 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N05 |
| AHFS class | 28:24.92 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | TEVA CANADA LIMITED |
How is it administered?
Initial: 5 mg 2-3 times daily. Titrate by 5 mg every 2-3 days. Usual dose: 20-30 mg daily. Max: 45 mg daily. Taper gradually to discontinue.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in provided text (Section 11 header present but content truncated). Standard practice is 15-30°C.
How is it supplied?
Bottles of 100 tablets.
Which pack is which?
| Strength on the label | 10 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Packaging as described in the monograph | Bottles of 100 tablets. |
| Storage | Not explicitly stated in provided text (Section 11 header present but content truncated). Standard practice is 15-30°C. |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Contraindications
Hypersensitivity to buspirone; severe hepatic or severe renal impairment; use within 14 days of MAO inhibitors (including methylene blue and linezolid).
Warnings and precautions
Risk of addiction, abuse, and misuse; life-threatening withdrawal symptoms; profound sedation/respiratory depression with opioids; serotonin toxicity; risk of falls/fractures.
Is BUSPIRONE in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N05BE01 BUSPIRONE. 7 of 25 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AMB-BUSPIRONE | 10 MG | TABLET | AMBICARE PHARMACEUTICALS INC. | MARKETED | DIN 02550555 |
| AURO-BUSPIRONE | 10 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02500213 |
| JAMP BUSPIRONE | 10 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02509911 |
| MINT-BUSPIRONE | 10 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | DIN 02519054 |
| PMS-BUSPIRONE | 10 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02230942 |
| PRO-BUSPIRONE | 10 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02223163 |
| APO-BUSPIRONE | 10 MG | TABLET | APOTEX INC | DORMANT | DIN 02211076 |
| BUSPAR TAB 10MG | 10 MG | TABLET | BRISTOL-MYERS SQUIBB CANADA | CANCELLED POST MARKET | DIN 00603821 |
| BUSPIRONE | 10 MG | TABLET | SANIS HEALTH INC | CANCELLED POST MARKET | DIN 02447851 |
| BUSPIRONE | 10 MG | TABLET | APOTEX INC | APPROVED | DIN 02207672 |
Who else supplies BUSPIRONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BUSPIRONE appears in 15 registered pack listings across 4 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does BUSPIRONE cost around the world?
BUSPIRONE is listed on 4 national price registers Nexara tracks, across 143 pack listings published on 4 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United States | acquisition | 5 | 130 | 03 Sep 2026 |
| Greece | producer price (ex-factory) | 9 | 9 | 03 Sep 2026 |
| United Kingdom | hospital | 2 | 2 | 31 Aug 2026 |
| South Africa | single exit price | 2 | 2 | 01 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.